ダウンロード数: 866
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
58_655.pdf | 644.41 kB | Adobe PDF | 見る/開く |
タイトル: | 腎癌分子標的治療の副作用対策 : 新規薬剤の有害事象プロファイル |
その他のタイトル: | Adverse Event Profile of New Targeted Agents for Renal Cell Carcinoma |
著者: | 野澤, 昌弘 植村, 天受 |
著者名の別形: | Nozawa, Masahiro Uemura, Hirotsugu |
キーワード: | Adverse event Immunotherapy Renal cell carcinoma Targeted therapy Tyrosine-kinase inhibitor |
発行日: | Nov-2012 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 58 |
号: | 11 |
開始ページ: | 655 |
終了ページ: | 657 |
抄録: | Temsirolimus is an inhibitor of mammalian target of rapamycin, with proven efficacy against advanced renal cell carcinoma (RCC), particularly poor risk and/or non-clear cell RCC, in a randomized first-line phase III trial. In this trial, adverse events (AEs) ≥grade 3 occurred in47. 6% of patients treated with temsirolimus alone (n=208), and the common AEs included asthenia, anemia and hyperglycemia. During the observation period of this trial, drug-related pneumonitis was detected ; 4 patients developed temsirolimus-related pneumonitis, including 2 with ≥grade 3. To date, there have not been any reports analyzing data from a large number of Japanese RCC patients treated with temsirolimus. However, judging from our experience, the severity as well as the frequency of AEs associated with temsirolimus in Japanese patients seem to be similar to those in the Western population. In this study, we summarize our clinical experience with the use of temsirolimus focusing on its AEs and try to clarify the characteristics of temsirolimus-related AEs in Japanese patients, and then present our data relevant to this point from our clinical studies in order to discuss the significance of the management of AEs encountered during treatment with temsirolimus. |
著作権等: | 許諾条件により本文は2013-12-01に公開 |
URI: | http://hdl.handle.net/2433/166339 |
PubMed ID: | 23254796 |
出現コレクション: | Vol.58 No.11 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。